Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025;PYX-201 and PYX-106 remain on track Webcast to be held today, May 24, at 9:00 a.m. ET BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. ("Pyx

-Patients with liposarcoma (LPS) demonstrated prolonged median PFS (mPFS) relative to historical controls treated with standard of care of doxorubicin- -Encouraging PFS data from the ongoing investigator sponsored trial in collaboration with Columbia University supports expansion of the LPS cohort to inform a potential phase 3 registration-enabling trial- -Apexigen to host investor call with sarcoma expert and principal investigator, Gary Schwartz, M.D. at Columbia University, today, November 14, at 8:00 a.m. ET- SAN CARLOS, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeu

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

4 - Apexigen, Inc. (0001814140) (Issuer)

SC 13G/A - Apexigen, Inc. (0001814140) (Subject)

SC 13G - Apexigen, Inc. (0001814140) (Subject)

SC 13G/A - Apexigen, Inc. (0001814140) (Subject)

NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of APGN and Pyxis Oncology, Inc. Under the terms of the proposed merger, APGN shareholders will receive 0.1725 shares of Pyxis Oncology, Inc. common stock for each share of APGN common stock owned. Following the merger, pre-merger Apexigen shareholders are expected to own approximately 10% of the outstanding equity of the combined company. If you are an APGN investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz

- Marked increases in overall survival observed across soft tissue sarcoma patients - - Demonstrated improvement of median progression free survival in patients with dedifferentiated liposarcoma (DDLPS) - - DDLPS expansion cohort enrolling to inform a potential Phase 3 registration trial - SAN CARLOS, Calif., June 03, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from a Phase 2 investigator-sponsored trial in collaboration with Columbia University, evaluating sotigalimab (sotiga), Ap

Pyxis Oncology positioned at forefront of Antibody-Drug Conjugate (ADC) development Commercially and clinically validated APXiMAB platform for antibody generation complements FACT ADC toolkit of linkers, payloads and conjugation chemistries previously obtained from Pfizer Sotigalimab, a potential best-in-class Phase 2 CD40 agonist, has demonstrated rapid, deep and durable responses across difficult-to-treat tumor types All-stock deal allows Pyxis Oncology to maintain cash runway into 1H 2025;PYX-201 and PYX-106 remain on track Webcast to be held today, May 24, at 9:00 a.m. ET BOSTON and SAN CARLOS, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. ("Pyx

SAN CARLOS, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that it has engaged Ladenburg Thalmann & Co. Inc. ("Ladenburg") to evaluate strategic alternatives for the Company with the goal of maximizing stockholder value. As part of this process, the Company will explore the potential for an acquisition, company sale, merger, divestiture of assets, licensing, or other strategic transactions. There can be no assurance that the exploration of strategic alternatives will result in any agreements or transactio

SAN CARLOS, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN), a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that it has entered into definitive agreements with new, biotechnology-focused investors for the issuance and sale of an aggregate of approximately 2.0 million shares of its common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an aggregate of approximately 2.0 million shares of common stock in a private placement offering. The purchase price per share and accompanying warrant is $1.40 (or $1.399 per pre-funded warra

-Results demonstrate sotigalimab's ability to turn immunologically "cold" tumors "hot" to increase anti-tumor immune responses for increased therapeutic effect in patients with esophageal/gastro-esophageal junction and rectal cancers- SAN CARLOS, Calif., Jan. 19, 2023 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced the presentation of new data from Phase 2 multicenter clinical trials evaluating sotigalimab (sotiga), Apexigen's agonist antibody targeting CD40, in two poster presentations at the ASCO Gastrointestinal Cancers Symp

-Ongoing Phase 2 trial in collaboration with Columbia University demonstrated that sotigalimab (sotiga) in combination with doxorubicin achieved a median progression-free survival (mPFS) of 12.45 months in patients with liposarcoma (LPS)- -Encouraging mPFS data supports expansion of the LPS cohort to inform a potential Phase 3 registration trial- -Presented positive Phase 2 esophageal/GEJ data at ESMO 2022 demonstrating that sotigalimab (sotiga) in combination with neoadjuvant chemoradiation led to increased pathologic complete response rates across patient subgroups and demonstrated sotiga's ability to turn "cold" tumors "hot"- -Presented positive Phase 1/2 metastatic melanoma data at S

-Patients with liposarcoma (LPS) demonstrated prolonged median PFS (mPFS) relative to historical controls treated with standard of care of doxorubicin- -Encouraging PFS data from the ongoing investigator sponsored trial in collaboration with Columbia University supports expansion of the LPS cohort to inform a potential phase 3 registration-enabling trial- -Apexigen to host investor call with sarcoma expert and principal investigator, Gary Schwartz, M.D. at Columbia University, today, November 14, at 8:00 a.m. ET- SAN CARLOS, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeu

SAN CARLOS, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that Company's Management will participate virtually in the H.C. Wainwright 24th Annual Global Investment Conference, to be held virtually and in New York, NY from September 12-14, 2022. H.C. Wainwright 24th Annual Global Investment Conference Format: Pre-recorded presentation and one-on-one investor meetingsDate: Monday, September 12, 2022Time: Presentation available at 7:00 a.m. ETWebcast: Click HereAn archived webcast of the presentation will

SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Apexigen, Inc. (NASDAQ:APGN) a clinical-stage company focused on developing innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology, today announced that the Company's Management will participate virtually in the Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022. 2022 Wedbush PacGrow Healthcare ConferenceFormat: Panel discussion and one-on-one investor meetingsTopic: For Your IOnly - Progress, Challenges in Immuno-OncologyPanel Date & Time: Tuesday, August 9, 2022 at 2:20 p.m. ETPanel Webcast: Click Here An archived webcast of the presentation will be accessible in the Even

EF Hutton analyst Tony Butler reiterates Apexigen (NASDAQ:APGN) with a Hold and maintains $0.64 price target.

Gainers HeartBeam (NASDAQ:BEAT) stock rose 20.1% to $2.42 during Thursday's pre-market session. The company's market cap stands at $62.6 million. Prelude Therapeutics (NASDAQ:PRLD) shares increased by 11.43% to $5.75. The market value of their outstanding shares is at $275.7 million. Benitec Biopharma (NASDAQ:BNTC) shares rose 10.36% to $0.23. The market value of their outstanding shares is at $6.4 million. Predictive Oncology (NASDAQ:POAI) shares moved upwards by 10.19% to $3.46. The market value of their outstanding shares is at $13.8 million. Bullfrog AI Hldgs (NASDAQ:BFRG) stock increased by 9.71% to $5.42. The company's market cap stands at $32.9 million. The company's, Q1 earnings

Pyxis Oncology Inc (NASDAQ:PYXS) agreed to acquire Apexigen Inc (NASDAQ:APGN) in an all-stock transaction for an implied value of $0.64 per Apexigen share.  Apexigen went public in a blank-check deal just last summer. For each share of Apexigen, Pyxis Oncology will issue 0.1725 shares of its common stock for a total enterprise value of approximately $16 million. In February, Apexigen announced evaluating alternatives and reduced its workforce by 55%. "This acquisition uniquely positions Pyxis Oncology at the forefront of antibody-drug conjugate (ADC) innovation by adding humanized antibody generation to our Flexible Antibody Conjugation Technology (FACT) ADC toolkit acquired from Pfize

Gainers Minerva Surgical (NASDAQ:UTRS) shares rose 153.3% to $0.46 during Wednesday's regular session. Trading volume for this security as of 13:30 EST is 82.3 million, which is 14267.1% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $81.4 million. Enveric Biosciences (NASDAQ:ENVB) stock rose 90.52% to $6.0. Trading volume for Enveric Biosciences's stock is 66.1 million as of 13:30 EST. This is 2999.9% of its average full-day volume over the last 100 days. The company's market cap stands at $12.4 million. Zura Bio (NASDAQ:ZURA) shares rose 34.01% to $7.17. As of 13:30 EST, this security is trading at a volume of 13.1 million share

Gainers Minerva Surgical, Inc. (NASDAQ:UTRS) shares jumped 209.1% to $0.5622 after the United States Patent and Trademark Office granted the company a patent for certain medical systems and methods. EpicQuest Education Group International Limited (NASDAQ:EEIQ) shares surged 88.4% to $2.75 after gaining 8% on Tuesday. EpicQuest Education's Davis College signed a non-binding Memorandum of Understanding with Chongqing College of Electronic Engineering. Enveric Biosciences, Inc. (NASDAQ:ENVB) jumped 85% to $5.83 after the company announced it received a Notice of Allowance from the USPTO for a patent application involving its EVM201 Series. GigaCloud Technology Inc. (NASDAQ:GCT) shares

Pyxis Oncology (NASDAQ:PYXS) has announced an acquisition of Apexigen (NASDAQ:APGN) that is expected to be completed in the second half of 2023. Under the terms of the agreement, Pyxis Oncology has agreed to give Apexigen $16 million in stock in exchange for APGN stock. About The Companies Involved Pyxis Oncology is a clinical-stage oncology company focused on developing a multi-modality portfolio of next-generation therapeutics to target difficult-to-treat cancers and improve the quality of life for patients. It develops the product candidates to directly kill tumor cells and address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evas

Gainers Minerva Surgical (NASDAQ:UTRS) stock moved upwards by 213.3% to $0.57 during Wednesday's pre-market session. The company's market cap stands at $100.8 million. Apexigen (NASDAQ:APGN) stock rose 40.1% to $0.56. The company's market cap stands at $13.8 million. Enveric Biosciences (NASDAQ:ENVB) shares increased by 33.65% to $4.21. The market value of their outstanding shares is at $8.7 million. Zura Bio (NASDAQ:ZURA) stock moved upwards by 23.55% to $6.61. The market value of their outstanding shares is at $210.2 million. vTv Therapeutics (NASDAQ:VTVT) shares moved upwards by 22.14% to $1.07. The company's market cap stands at $87.1 million. Immutep (NASDAQ:IMMP) stock increased

EF Hutton analyst Tony Butler maintains Apexigen (NASDAQ:APGN) with a Buy and lowers the price target from $8 to $5.